Skip to main content
Have a personal or library account? Click to login
Coumarin derivatives against amyloid-beta 40 – 42 peptide and tau protein Cover

Coumarin derivatives against amyloid-beta 40 – 42 peptide and tau protein

Open Access
|Sep 2022

Abstract

In preclinical studies, simple coumarins (scoparone, limettin) and furanocoumarins (imperatorin, xanthotoxin, bergapten) have already found to demonstrate procognitive abilities. This suggests that they hold antioxidative, anti-inflammatory and inhibitory action towards acetylcholinesterase activities. However, little is known about their influence on the amyloidal structure formation, the leading cause of Alzheimer’s disease (AD). In vitro and in cellulo assays were applied to evaluate the effect of selected coumarins on the different stages of Aβ40/42 and tau protein aggregation. Kinetic analyses were performed to evaluate their inhibiting abilities in time. Limettin revealed the most potent inhibiting profile towards Aβ40 aggregation, however, all tested compounds presented low influence on Aβ42 and tau protein aggregation inhibition. Despite the preliminary stage of the project, the promising effects of coumarins on Aβ40 aggregation were shown. This suggests the coumarin scaffold can serve as a potential multitarget agent in AD treatment, but further studies are required to confirm this.

DOI: https://doi.org/10.2478/cipms-2022-0013 | Journal eISSN: 2300-6676 | Journal ISSN: 2084-980X
Language: English
Page range: 67 - 74
Submitted on: Mar 13, 2022
Accepted on: Jun 17, 2022
Published online: Sep 2, 2022
Published in print: Aug 1, 2022
Published by: Sciendo
In partnership with: Paradigm Publishing Services

© 2022 Joanna Kowalczyk, Krystyna Skalicka-Wozniak, Barbara Budzynska, Nesrine El Sayed, Alba Espargaró, Raimon Sabate, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.